MedTrace Logo

To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation

NCT04728971 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-08-16

No results posted yet for this study

Summary

To evaluate the clinical success rate of micafungin in preventing invasive mycosis after liver transplantation.

Conditions

  • Liver Transplantation

Interventions

DRUG

Micafungin Sodium 50 MG Injection

Give Micafungin 150 mg/d within 24 hours after liver transplantation.

DRUG

Caspofungin Acetate

Give Caspofungin 35 mg/d lasts 1 week after liver transplantation.

Sponsors & Collaborators

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2025-10-01
Completion
2026-02-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04728971 on ClinicalTrials.gov